Intercept’s US president Vivek Devaraj said the pharma company still believes in the evidence supporting the liver disease ...
Ipsen to present new data on elafibranor at The Liver Meeting® 2024Launch of Iqirvo® (elafibranor)1 on track with ...
The sNDA was submitted to support full approval of OCA for this indication based on data from the COBALT trial, as well as real-world evidence.
By Bhanvi Satija and Puyaan Singh (Reuters) - The U.S. Food and Drug Administration on Tuesday declined full approval for ...
Journalist Annie Lowrey has a rare disease that causes a near-constant itch that doesn't respond to most treatments. She ...
In the wake of an unfavorable advisory committee meeting in September, Intercept Pharmaceuticals’ bid to win full approval ...
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA declined to grant full approval to ...
The lead clinical asset, TH104, aims to suppress chronic pruritus associated with primary biliary cholangitis (PBC), a rare autoimmune liver disease with no known cure. The expanded pipeline includes ...
Primary school in Dublin forced to close and send pupils home following security alert A Dublin primary school had to close last week and send all pupils home over a security alert in which ...
the Company's lead clinical-stage candidate for moderate-to-severe pruritus in primary biliary cholangitis (PBC). The EMA interactions specifically focused on both the Phase 2 and Phase 3 clinical ...
About Pruritus and Primary Biliary Cholangitis According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health, PBC is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback